-
Leptomeningeal metastases in patients with human epidermal growth factor receptor 2 positive breast cancer : real-world data from a multicentric European cohortRatoša, Ivica ...In patients with human epidermal growth factor receptor 2 positive (HER2+) breast cancer, leptomeningeal metastases (LM) are a rare but often a fatal clinical scenario. In this multicentric study, ... clinical and pathologic characteristics of patients with HER2+ breast cancer developing LM were described, as well as survival outcomes. Data were gathered retrospectively from medical records of 82 patients with advanced HER2+ breast cancer and LM treated between August 2005 and July 2020. Following LM diagnosis, 79 (96.3%) patients received at least one line of anti-HER2 therapy, 25 (30.5%) patients received intrathecal therapy and 58 (70.7%) patients received radiotherapy. Overall survival (OS) was 8.3 months (95% confidence interval [CI] 5.7-11), 1-year OS was 42%, and 2-year OS was 21%. At univariate analysis, patients who were treated after 2010, had better Karnofsky performance status, were free of neurological symptoms, had better prognostic, received chemotherapy (OS difference 9.4 months, P = .024), or monoclonal antibodies (trastuzumab ± pertuzumab; OS difference 6.1 months; P = .013) after LM diagnosis, had a statistically significantly longer OS. Presence of neurological symptoms (hazard ratio 3.32, 95% CI 1.26-8.73; P = .015) and not having received radiotherapy (hazard ratio 2.02, 95% CI 1.09-3.72; P = .024) were all associated with poorer OS at multivariate analysis. To summarize, not having neurological symptoms and receiving RT at LM diagnosis were associated with prolonged OS in our cohort. Survival seemed to be prolonged with multimodality treatment, which included targeted therapy, chemotherapy, and RT to the LM sites.Source: International journal of cancer = Journal international du cancer. - ISSN 0020-7136 (Vol. 151, no. 8, 2022, str. 1355-1366)Type of material - article, component partPublish date - 2022Language - englishCOBISS.SI-ID - 113122563
Author
Ratoša, Ivica |
Dobnikar, Nika, zdravnica |
Bottosso, Michele |
Dieci, Maria Vittoria |
Jacot, William |
Pouderoux, Stéphane |
Ribnikar, Domen |
Sinoquet, Léa |
Guarneri, Valentina |
Žnidarič, Tanja, zdravnica
Topics
anti-HER2 zdravljenje |
rak dojke |
receptor 2 humanega epidermalnega rastnega faktorja |
radioterapija |
anti-HER2 therapy |
breast cancer |
human epidermal growth factor receptor 2 |
radiotherapy
Shelf entry
Permalink
- URL:
Impact factor
Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.
| Year | Impact factor | Edition | Category | Classification | ||||
|---|---|---|---|---|---|---|---|---|
| JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP | |
Impact factor
Select the library membership card:
DRS, in which the journal is indexed
| Database name | Field | Year |
|---|
| Links to authors' personal bibliographies | Links to information on researchers in the SICRIS system |
|---|---|
| Ratoša, Ivica | 34883 |
| Dobnikar, Nika, zdravnica | ![]() |
| Bottosso, Michele | ![]() |
| Dieci, Maria Vittoria | ![]() |
| Jacot, William | ![]() |
| Pouderoux, Stéphane | ![]() |
| Ribnikar, Domen | 36202 |
| Sinoquet, Léa | ![]() |
| Guarneri, Valentina | ![]() |
| Žnidarič, Tanja, zdravnica | 56356 |
Select pickup location:
Material pickup by post
Notification
Subject headings in COBISS General List of Subject Headings
Select pickup location
| Pickup location | Material status | Reservation |
|---|
Please wait a moment.
